A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
Public ClinicalTrials.gov record NCT06182124. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1/2, RANDOMIZED, DOUBLE-BLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to learn about the safety and immune effects of a pneumococcal vaccine in adults. This vaccine can possibly provide protection against further pneumococcal disease. This study will happen in 4 stages: Stage 1 is seeking participants who are between 18 years to 49 years of age. The participants will receive 1 of 2 pneumococcal vaccine candidates (different formulations) or 20vPnC (Prevnar 20) as a single shot given into the upper arm muscle. Stage 2 will begin after participants have completed Stage 1, and a pneumococcal vaccine candidate has been decided. Stage 2 is seeking participants who are adults 50 years of age and older. The participants will receive the chosen pneumococcal vaccine candidate from Stage 1 or 20vPnC (Prevnar 20). The vaccines will be given as a single shot into the upper arm muscle. Stage 3 is seeking participants who are adults 50 years of age and older. The participants will receive the chosen pneumococcal vaccine candidate from Stage 1 or a licensed pneumococcal comparator vaccine. The vaccines will be given as a single shot into the upper arm muscle. Stage 4 is seeking participants who are adults 50 years of age and older. The participants will receive either one of three pneumococcal vaccine candidates or one of two licensed pneumococcal comparator vaccines. The vaccines will be given as a single shot into the upper arm muscle. Participants will take part in this study for about 6 months for Stage 1, Stage 3, and Stage 4 and 12 months for Stage 2. During this time participants will have from 2 to 4 clinic visits and 1 phone visit. At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during these clinic visits.
Study identification
- NCT ID
- NCT06182124
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 1,710 participants
Conditions and interventions
Conditions
Interventions
- Multivalent Pneumococcal Vaccine - Formulation 1 Biological
- Multivalent Pneumococcal Vaccine - Formulation 2 Biological
- 20-valent pneumococcal conjugate vaccine (20vPnC) Biological
- Licensed pneumococcal comparator vaccine Biological
- Multivalent Pneumococcal Vaccine - Formulation 3 Biological
- Multivalent Pneumococcal Vaccine - Formulation 4 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 20, 2023 (Actual)
- Primary completion
- May 12, 2026 (Actual)
- Completion
- May 12, 2026 (Actual)
- Last update posted
- Sep 25, 2026
2023 – 2026
United States locations
- U.S. sites
- 20
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alliance for Multispecialty Research, LLC | Doral | Florida | 33172 | — |
| Indago Research & Health Center, Inc | Hialeah | Florida | 33012 | — |
| Clinical Research Atlanta | Stockbridge | Georgia | 30281 | — |
| Optimal Research | Peoria | Illinois | 61614 | — |
| Alliance for Multispecialty Research, LLC | New Orleans | Louisiana | 70119 | — |
| Headlands Research - Detroit | Southfield | Michigan | 48034 | — |
| Rochester Clinical Research, LLC | Rochester | New York | 14609 | — |
| IMA Evaluations, LLC dba IMA Clinical Research | Tarrytown | New York | 10591 | — |
| Accellacare - Wilmington | Wilmington | North Carolina | 28401 | — |
| AMR Clinical | Knoxville | Tennessee | 37909 | — |
| AMR Clinical | Knoxville | Tennessee | 37920 | — |
| Headlands Horizons LLC | Brownsville | Texas | 78526 | — |
| DM Clinical Research- Cyfair | Houston | Texas | 77065 | — |
| Clinical Trials of Texas, LLC dba Flourish Research | San Antonio | Texas | 78229 | — |
| IMA Clinical Research San Antonio | San Antonio | Texas | 78229 | — |
| Dynamed Clinical Research, LP d/b/a DM Clinical Research | Sugarland | Texas | 77478 | — |
| DM Clinical Research | Tomball | Texas | 77375 | — |
| Dynamed Clinical Research, LP d/b/a DM Clinical Research | Tomball | Texas | 77375 | — |
| J. Lewis Research, Inc. / Foothill Family Clinic | Salt Lake City | Utah | 84109 | — |
| J. Lewis Research, Inc. | Salt Lake City | Utah | 84109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06182124, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06182124 live on ClinicalTrials.gov.